AQW051   Click here for help

GtoPdb Ligand ID: 7371

Synonyms: AQW-051 | VQW 765 | VQW-765 | VQW765
Compound class: Synthetic organic
Comment: AQW 051 is an α7 nicotinic acetylcholine receptor (nAChR) partial agonist from Novartis for the oral treatment of cognitive deficits in schizophrenia, Alzheimer's, and Parkinson's diseases [1,3]. Structure first disclosed at March 2014 ACS meeting. The (3S) version is CID 71553840. The compound was later re-named to VQW-765 (Vanda Pharmaceuticals).
Click here for help
2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 2
Hydrogen bond donors 0
Rotatable bonds 3
Topological polar surface area 25.36
Molecular weight 294.17
XLogP 3.57
No. Lipinski's rules broken 0
Click here for help
Canonical SMILES Cc1ccc(cc1)c1ccc(cn1)OC1CN2CCC1CC2
Isomeric SMILES Cc1ccc(cc1)c1ccc(cn1)O[C@H]1CN2CCC1CC2
InChI InChI=1S/C19H22N2O/c1-14-2-4-15(5-3-14)18-7-6-17(12-20-18)22-19-13-21-10-8-16(19)9-11-21/h2-7,12,16,19H,8-11,13H2,1H3/t19-/m0/s1
1. Di Paolo T, Grégoire L, Feuerbach D, Elbast W, Weiss M, Gomez-Mancilla B. (2014)
AQW051, a novel and selective nicotinic acetylcholine receptor α7 partial agonist, reduces l-Dopa-induced dyskinesias and extends the duration of l-Dopa effects in parkinsonian monkeys.
Parkinsonism Relat Disord, 20 (11): 1119-23. [PMID:25172125]
2. Di Paolo, Thérèse et. al. (2011)
Use of nicotinic acetylcholine receptor alpha 7 activators.
Patent number: WO2011036167. Assignee: Novartis. Priority date: 22/09/2009. Publication date: 31/03/2011.
3. Feuerbach D, Pezous N, Weiss M, Shakeri-Nejad K, Lingenhoehl K, Hoyer D, Hurth K, Bilbe G, Pryce CR, McAllister K et al.. (2015)
AQW051, a novel, potent and selective α7 nicotinic ACh receptor partial agonist: pharmacological characterization and phase I evaluation.
Br J Pharmacol, 172 (5): 1292-304. [PMID:25363835]
4. Hurth K, et. al. 
MEDI 222: Identification of AQW051, an alpha7 nicotinic acetylcholine receptor partial agonist for the treatment of cognitive impairment associated with schizophrenia.
Accessed on 06/04/2014. Modified on 06/04/2014. ACS Med Chem Meeting Abstracts, March 2014,
5. Trenkwalder C, Berg D, Rascol O, Eggert K, Ceballos-Baumann A, Corvol JC, Storch A, Zhang L, Azulay JP, Broussolle E et al.. (2016)
A Placebo-Controlled Trial of AQW051 in Patients With Moderate to Severe Levodopa-Induced Dyskinesia.
Mov Disord, 31 (7): 1049-54. [PMID:26990766]